Premium
(‐)‐Epicatechin: cardiometabolic clinical effects supported by preclinical model (829.2)
Author(s) -
GutierrezSalmean Gabriela,
Ortiz Pilar,
Ramirez Israel,
Meaney Eduardo,
Villarreal Francisco,
Ceballos Guillermo
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.829.2
Subject(s) - hypertriglyceridemia , postprandial , medicine , endocrinology , obesity , weight loss , weight gain , blood pressure , adipose tissue , lipid metabolism , cholesterol , triglyceride , body weight , diabetes mellitus
Background . Obesity associates with cardiometabolic disruptions. Lifestyle changes and pharmacologic therapies show moderately effective results. (‐)‐Epicatechin (EPI), the most abundant flavanol in cacao, has been associated with better cardiometabolic health. Objective . To assess the effect of EPI in humans and explain findings through a preclinical study. Methods . In humans, we performed a single‐dose of EPI oral metabolic tolerance test and a 1‐week trial, measuring cardiometabolic endpoints. In rats, we induced weight gain and cardiometabolic disruptions by a high‐fat diet; afterwards, EPI was daily administered for 15 days. Weight gain, glycemia, arterial pressure, triglyceridemia, and HDL‐cholesterol were measured; also, immonublot in skeletal muscle and adipose tissue were performed. Results . EPI enhanced lipid oxidation and attenuated hyperglycemia and hypertriglyceridemia during postprandial metabolism. EPI induced weight‐loss, fat loss, and improved cardiometabolic endpoints in humans. In rats, EPI reduced weight gain, blood triglycerides, and hyperglycemia. EPI increased the expression of sirtuins, PCG‐1α, mitofilin, UCP. Conclusions . EPI improved several cardiometabolic risk factors in both humans and animals by modulating energy metabolism. These findings make EPI an attractive candidate for human use in regards of treating obesity and its associated comorbidities.